Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial

التفاصيل البيبلوغرافية
العنوان:	Efficacy and Safety of Pembrolizumab in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMBCL): Updated Analysis of the Keynote-170 Phase 2 Trial
المؤلفون:	Zinzani, Pier Luigi, Thieblemont, Catherine, Melnichenko, Vladimir, Bouabdallah, Krimo, Walewski, Jan, Majlis, Alejandro, Fogliatto, Laura, Caballero, Dolores, Christian, Beth, Gulbas, Zafer, Özcan, Muhit, Salles, Gilles Andre, Shipp, Margaret A., Chatterjee, Arkendu, Orlowski, Robert J, Balakumaran, Arun, Armand, Philippe
المصدر:	Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p2833-2833, 1p
مستخلص:	Introduction.In rrPMBCL, treatment outcomes with current therapies remain poor. Similar to classical Hodgkin lymphoma, PMBCL frequently exhibits 9p24.1/ PD-L1/ PD-L2copy number alterations and rearrangements with associated PD-L1 and/or PD-L2 overexpression, which may facilitate immune evasion. The genetics of PMBCL could thus make it particularly susceptible to PD-1 blockade. In the phase 1 KEYNOTE-013 (NCT01953692) trial, the anti-PD-1 antibody pembrolizumab showed promising antitumor activity against rrPMBCL. KEYNOTE-170 (NCT02576990) is an ongoing, two-cohort, multicenter, Phase 2 study evaluating the efficacy and safety of pembrolizumab in patients with rrPMBCL and in patients with Richter syndrome. Here we report updated interim results and biomarker data from the rrPMBCL cohort of KEYNOTE-170.
قاعدة البيانات:	Supplemental Index

الوصف
تدمد:	00064971 15280020
DOI:	10.1182/blood.V130.Suppl_1.2833.2833